9vHPV Vaccine
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
Feb 18, 2022 → May 25, 2029
NCT ID
NCT05285826About 9vHPV Vaccine
9vHPV Vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT05285826. Target conditions include Papillomavirus Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05450705 | Phase 3 | Active |
| NCT05314023 | Phase 3 | Active |
| NCT05285826 | Phase 3 | Active |
| NCT04772534 | Phase 3 | Completed |
| NCT04708041 | Phase 3 | Active |
| NCT04199689 | Phase 3 | Active |
| NCT03546842 | Phase 3 | Completed |
| NCT01651949 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections